Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:VIVO

Meridian Bioscience (VIVO) Stock Price, News & Analysis

Meridian Bioscience logo

About Meridian Bioscience Stock (NASDAQ:VIVO)

Key Stats

Today's Range
$33.97
$33.97
50-Day Range
$33.00
$33.97
52-Week Range
$20.35
$34.38
Volume
N/A
Average Volume
973,737 shs
Market Capitalization
$1.50 billion
P/E Ratio
35.02
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Meridian Bioscience Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
21st Percentile Overall Score

VIVO MarketRank™: 

Meridian Bioscience scored higher than 21% of companies evaluated by MarketBeat, and ranked 867th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Meridian Bioscience.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Meridian Bioscience is 35.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.45.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Meridian Bioscience is 35.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.13.

  • Price to Book Value per Share Ratio

    Meridian Bioscience has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for VIVO.
  • Dividend Yield

    Meridian Bioscience does not currently pay a dividend.

  • Dividend Growth

    Meridian Bioscience does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for VIVO.
  • Search Interest

    6 people have searched for VIVO on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Meridian Bioscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.30% of the stock of Meridian Bioscience is held by insiders.

  • Percentage Held by Institutions

    89.72% of the stock of Meridian Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Meridian Bioscience's insider trading history.
Receive VIVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter.

VIVO Stock News Headlines

9 hidden AI stocks set to thrive in Trump’s new era
AI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be worth trillions of dollars (here’s how to tap into this new wealth)
Meridian Growth Legacy MERDX
Biomerica, Inc. (BMRA)
Meridian Meadows Transitional Care
See More Headlines

VIVO Stock Analysis - Frequently Asked Questions

Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its quarterly earnings results on Friday, November, 12th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.21 by $0.03. The firm had revenue of $76.20 million for the quarter, compared to analyst estimates of $68.40 million. Meridian Bioscience had a net margin of 12.70% and a trailing twelve-month return on equity of 16.74%.

The following companies are subsidiaries of Meridian Bioscience: Exalenz Bioscience.

Based on aggregate information from My MarketBeat watchlists, some other companies that Meridian Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Micron Technology (MU) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/12/2021
Today
11/24/2024
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:VIVO
CUSIP
58958410
Employees
702
Year Founded
1977

Profitability

Net Income
$42.46 million
Pretax Margin
16.31%

Debt

Sales & Book Value

Annual Sales
$333.02 million
Cash Flow
$1.78 per share
Book Value
$8.41 per share

Miscellaneous

Free Float
42,996,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
0.23

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:VIVO) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners